Faeth Therapeutics

Please join us in welcoming two extraordinary leaders to our Board of Directors: Dr. Stephen Hahn (Steve Hahn) and Dr. Jayson Dallas (Jayson Dallas) 🔬 Dr. Hahn brings unparalleled insights from his time as FDA Commissioner, Chief Medical Executive at MD Anderson, and his decades of oncology experience. His perspective on leveraging metabolism and AI to combat cancer will help guide our clinical and regulatory strategies. 💡 Dr. Dallas brings deep commercial and operational experience, having led Aimmune Therapeutics to its successful acquisition by Nestlé Health Science. His track record in driving innovation from early development to commercialization will be a valuable resource in driving our business forward. With their combined expertise, Faeth is poised to advance our mission of rethinking cancer using metabolism. Our CEO, Anand Parikh, says it best: "Their expertise in oncology, regulatory strategy, and biotech commercialization is invaluable as we accelerate our clinical programs and develop our MetabOS platform." https://lnkd.in/gch_UQCv

We’re excited to share that Faeth Therapeutics has made a donation of drug supply products to the Daman Oncology Center in Sudan, offering critical support to patients who need it most. This initiative is a true manifestation of one of our core values—CARE—which drives us to expand access to life-saving treatments wherever possible. A special thank you to Michael G., whose tireless efforts and determination ensured that this donation happened despite numerous roadblocks along the way. Additional thanks to Debbie Chirnomas and Francois Nicol, Ph.D. who ensured that this valuable package got to its destination in Sudan. It’s moments like these that remind us why we do what we do—to bring hope and healing to patients around the world. We are proud to contribute in any way we can and to work alongside passionate individuals who live and breathe our values every day.

The potential of Artificial Intelligence to accelerate medical discovery is immense, particularly within biology, writes CEO and Co-Founder, Anand Parikh. Unlike the more predictable fields of chemistry and physics, biology presents unique challenges due to its complexity and constant adaptation, areas where AI can play a transformative role but has been limited to date due to this dynamism. Embracing AI in biology means tackling some of the most complex and variable aspects of science for the very first time. By focusing AI’s power on the untapped potential of the metabolic genome in cancer research, for example, we are not just making incremental improvements but are positioned to make quantum leaps in understanding, managing and treating cancer. This is key to unlocking novel strategies that could serve as the fourth pillar of cancer treatment, alongside surgery, chemotherapy, and radiation. This innovative approach could fundamentally transform cancer care, providing personalized, effective treatments based on the metabolic profiling of individual tumors and a patient’s likely reactions to multiple therapeutic approaches. By doing so, we are setting the stage for discoveries that could fundamentally alter our approach to health and disease, making biology the next great frontier for AI. Read more here via Drug Discovery & Development:  https://lnkd.in/gA3A9sgS #CancerResearch #PrecisionMedicine #AIinBiology

Our CEO Anand Parikh will be participating in 1-on-1 investor meetings at the upcoming Jefferies Global Healthcare Conference from June 4-6 in New York. You can schedule a meeting by contacting bridie@faeththerapeutics.com. Faeth is focused on developing therapies targeting cancer metabolism. The role of metabolism in cancer proliferation is well established, yet remains a vastly under-exploited area, with very few cancer metabolism therapies in existence today. Faeth’s differentiated approach to targeting cancer metabolism leverages a systemic understanding of cancer metabolism, functional genomics, and computational biology to develop effective, less toxic therapies. https://lnkd.in/gMzeWZkJ

A great interview with Faeth Therapeutics co-founder Siddhartha Mukherjee with Andrew Dunn at Endpoints News on the doctor-writer worldview, #AI, the future of cancer and the work Faeth just completed in endometrial cancer patients. Faeth just completed a pivotal study using our “PIKTOR” program, which is a combination of inhibition of PI3Kinase and mTOR, along with chemo, in patients that had been heavily pretreated with chemo alone. We saw a strong, pretty unprecedented signal in endometrial cancer patients, and that is what is being followed up. Faeth isn’t a “diet” company, but our mission is to tackle cancer metabolism as a whole. And PIKTOR, which attacks two crucial nodes of cancer metabolism is the best example. I don’t think anyone has seen this sort of a response in endometrial cancer — multiple CRs in heavily pre-treated patients. So it’s a nail-biting time for us. I should say Faeth isn’t JUST a “diet” company. It’s a company that focuses on all aspects of metabolism. Sometimes by changing the metabolic state of a patient (eg. by depletion of a nutrient, or changing metabolic signaling). But the PIKTOR program uses the same principles to attack the cancer cell’s internal metabolic program. https://lnkd.in/g5H4a-AA

Faeth Therapeutics is transforming cancer treatment through metabolic approaches. CEO + Co-Founder Anand Parikh talks about their mission, the metabolic approach to cancer treatment, and the role of technology in the drug discovery process on #NYSEFloorTalk with Judy Khan Shaw.

Thank you NYSE, Judy Khan Shaw and Eric J. Dimise, PhD for hosting Faeth CEO Anand Parikh today to discuss how we are leveraging comprehensive #metabolicdata and #ML to inform a tumor metabolism-focused approach to #cancer treatment.

Our latest study, leveraging insights from metabolic signaling, is giving some patients with cancer a new hope. CEO Anand Parikh tells Abigail Beaney with Clinical Trials Arena, that he has reservations, saying metabolic drugs like GLP1ra’s are unlikely to be effective enough as monotherapies for some indications, but believes there is real promise as combination therapies.  “The concept of metabolic synthetic lethalities, where you hit the genetics of whatever disease you're looking at, but then you use metabolism to block the resistance pathways or the escape pathways. This is going to be a really interesting ticket that I think has applicability, way beyond cancer, rare disease, or inborn errors of metabolism or even cardiometabolic disease,” 🔗 Read the full interview and learn more about the applications of GLP-1’s beyond weight loss. https://lnkd.in/diPpnAcz #canceresearch #clinicaltrials #obesitydrugs

The recent The Wall Street Journal Journal report from Brianna Abbott on the rising toll of uterine cancer is a stark reminder of the urgent need for innovative approaches in the fight against this deadly disease. – Uterine cancer is now the deadliest gynecologic cancer in the U.S., with survival rates declining over the past four decades. – The incidence of uterine cancer is increasing, particularly among Black and Hispanic women, highlighting significant racial disparities in both diagnosis and treatment. – Obesity and rising rates of metabolic diseases are contributing factors to the increase in uterine cancer cases. It is crucial that all women, regardless of race or socioeconomic status, have access to the latest advancements in treatment and early detection. #UterineCancer #CancerResearch #WomensHealth https://lnkd.in/gJKMxPTE